<DOC>
	<DOCNO>NCT01494363</DOCNO>
	<brief_summary>1 . Goals The primary goal phase II trial : evaluate response rate combination chemotherapy Fluorouracil , Leucovorin , Oxaliplatin , Irinotecan patient locally advance metastatic Biliary tract cancer first-line chemotherapy Secondary goal : evaluate treatment-related toxicity combination , investigate progression-free survival ( PFS ) overall survival ( OS ) population 2 . Design The proposed clinical trial open label , non-comparative , multicenter phase II trial accord two stage test design Simon two-stage testing procedure</brief_summary>
	<brief_title>Phase II Study FOLFOXIRI Patients With Locally Advanced Metastatic Biliary Tract Cancer</brief_title>
	<detailed_description />
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Patients diagnose adenocarcinoma gallbladder biliary tract histologically cytologically 2 . Unresectable locally advanced , metastatic , recurrent biliary tract cancer 3 . Patients must ≥ 18 , ≤ 75 year old age 4 . ECOG performance status ≤ 2 5 . At least one lesion measure imaging ( CT/MRI ) accord Response Evaluation Criteria Solid Tumors ( RECIST v1.1 ) 6 . Estimated life expectancy 3 month 7 . Adequate bone marrow function ( absolute neutrophil count [ ANC ] ≥ 1,500/µL , hemoglobin ≥ 9.0 g/dL [ correction transfusion acceptable ] , platelet ≥ 100,000/µL ) 8 . Adequate kidney function ( serum creatinine &lt; 1.5 x upper limit normal [ ULN ] ) 9 . Adequate liver function ( serum total bilirubin &lt; 3.0xULN ; serum transaminases level &lt; 5.0xUNL ) 10 . Provision fully inform consent prior study specific procedures 1 . Other tumor type adenocarcinoma 2 . Any previous history chemotherapy biliary tract cancer ( prior neoadjuvant/adjuvant chemotherapy allow , recurrence occur 6 month completion previous chemotherapy ) 3 . Patients second primary cancer ( except , adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , solid tumor curatively treat evidence disease ≥5 year ) 4 . Patients receive radiotherapy target lesion within 6 month prior study treatment 5 . Patients defect central nervous system ( CNS ) psychiatric disorder CNS metastases 6 . Patients receive major surgery within 4 week start study treatment recover effect major surgery 7 . Pregnant breastfeed woman woman childbearing potential employ adequate contraception 8 . Other serious illness medical condition A. Clinically significant cardiac disease ( uncontrolled congestive heart disease despite treatment [ NYHA class III IV ] , symptomatic coronary artery disease , unstable angina myocardial infarction , conduction abnormality like grade 2 AV block , serious arrhythmia need medication , uncontrolled hypertension ) within 6 month prior study entry B. Liver cirrhosis ( ≥ ChildPugh class B ) C. History significant neurologic psychiatric disorder include dementia seizure D. Active uncontrolled infection E. Other serious underlie medical condition could impair ability patient participate study 9 . Concomitant administration experimental drug investigation , concomitant chemotherapy , hormonal therapy , immunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>